REG - N4 Pharma PLC - Holding(s) in Company

N4 PharmaAnnouncement

21/05/2020 16:30

RNS Number : 6711N
  
N4 Pharma PLC
  
21 May 2020
  
 

21 May 2020
 
N4 Pharma plc
("N4 Pharma" or the "Company")
 
Holding in Company
 
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has been notified that Mr David Farrier's beneficial interest in the Company's share capital remains at 12,175,510 ordinary shares in the Company, representing 8.00 per cent. of the Company's issued share capital. Mr Farrier's holding was diluted through a notifiable threshold as a result of the issue of new ordinary shares in the Company pursuant to the placing announced on 13 May 2020.
 
Enquiries:
 



N4 Pharma Plc
Nigel Theobald, CEO


 
Via Scott PR




Allenby Capital Limited
James Reeve/Asha Chotai


Tel: +44(0)203 328 5656




Turner Pope Investments (TPI) Ltd
Andrew Thacker


Tel: +44(0)20 3657 0050




Scott PR
Georgia Smith


 Tel: +44(0)1477 539 539 



 
About N4 Pharma
 
N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.
 
N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.
 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
HOLFLFFEESILFII